Artiva Biotherapeutics Inc. (ARTV) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Artiva Biotherapeutics In...

    NASDAQ: ARTV · Real-Time Price · USD
    2.99
    0.11 (3.82%)
    At close: Sep 25, 2025, 3:59 PM
    3.00
    0.33%
    After-hours: Sep 25, 2025, 07:19 PM EDT

    Artiva Biotherapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 251K 33.49M 4.93M 2M
    Cost of Revenue
    		 n/a n/a n/a n/a
    Gross Profit
    		 251K 33.49M 4.93M 2M
    Operating Income
    		 -67.28M -30.67M -59.83M -53.27M
    Interest Income
    		 5.35M 2.54M 1.29M n/a
    Pretax Income
    		 -58.49M -27.62M -58.34M -71.83M
    Net Income
    		 -58.49M -27.7M -58.39M -71.83M
    Selling & General & Admin
    		 17.2M 13.91M 20.78M 12.86M
    Research & Development
    		 50.33M 50.25M 43.98M 42.41M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 67.53M 64.16M 64.76M 55.27M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 67.53M 64.16M 64.76M 55.27M
    Income Tax Expense
    		 n/a 72K 53K n/a
    Shares Outstanding (Basic)
    		 11.26M 23.28M 17.58M 17.58M
    Shares Outstanding (Diluted)
    		 11.26M 23.28M 17.58M 17.58M
    EPS (Basic)
    		 -5.2 -1.19 -3.32 -4.08
    EPS (Diluted)
    		 -5.2 -1.19 -3.32 -4.08
    EBITDA
    		 -64.85M -28.41M -58.67M -71.58M
    EBIT
    		 -67.28M -30.67M -59.83M -71.83M
    Depreciation & Amortization
    		 2.43M 2.27M 1.16M 248K

    Add to Watchlist